Disease · MONDO_0010811
benign prostatic hyperplasia
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. benign prostatic hyperplasia. Diseases, record MONDO_0010811. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0010811
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
Adenofibromatous hypertrophy of prostate, Adenofibromatous hypertrophy of prostate, NOS, Adenoma, Prostatic, Adenomas, Prostatic, Adenomyomatous hyperplasia of prostate gland, BEP - Benign enlargement of prostate, BPH, BPH - Benign prostatic hypertrophy, Benign adenoma of prostate, Benign enlargement of prostate, Benign enlargement of prostate, NOS, Benign fibroma of prostate, Benign myoma of prostate, Benign prostatic hyperplasia (disorder), Benign prostatic hyperplasia, NOS, Enlarged prostate - benign, Fibromuscular hyperplasia of prostate gland, Glandular, stromal AND/OR muscular hyperplasia of prostate gland, Glandular, stromal and muscular hyperplasia of prostate gland, Hyperplasia of prostate, Hyperplasia of prostate (disorder), Hyperplasia of prostate, NOS, Hyperplasia, Prostatic, Hypertrophy (benign) of prostate, Hypertrophy, Benign Prostatic, Lobular hyperplasia of prostate gland, Nodular hyperplasia of prostate gland, Prostatauxe, Prostatic Adenoma, Prostatic Adenomas, Prostatic Hyperplasia, Prostatic Hyperplasia, Benign, Prostatic Hypertrophy, Benign, Prostatic area hypertrophy, Prostatic hyper -benign, Prostatic hypertrophy, benign hyperplasia of prostate, benign hyperplasia of the prostate, benign hypertrophy of prostate NOS, benign prostate hyperplasia, benign prostatic Hypertrophy, benign prostatic hyperplasia (disease), benign prostatic hyperplasia - BPH
- Open Targets
- Highest stage of its drugs
- Approval, for 14 of its 64 drugs, from ATC, DailyMed, EMA Human Drugs, FDA, PMDA and TTD
- Open Targets
Drugs64
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| TAMSULOSIN | CHEMBL836 | Small molecule | Approval | ATC and TTD | 44 | 41 | 36 | Drugs and targets |
| TADALAFIL | CHEMBL779 | Small molecule | Approval | DailyMed and PMDA | 30 | 20 | 20 | Drugs and targets |
| DUTASTERIDE | CHEMBL1200969 | Small molecule | Approval | ATC, DailyMed, PMDA and TTD | 29 | 20 | 19 | Drugs and targets |
| FINASTERIDE | CHEMBL710 | Small molecule | Approval | ATC, DailyMed and TTD | 51 | 11 | 11 | Drugs and targets |
| ALFUZOSIN | CHEMBL709 | Small molecule | Approval | ATC and TTD | 13 | 11 | 11 | Drugs and targets |
| SILODOSIN | CHEMBL24778 | Small molecule | Approval | ATC, DailyMed, EMA Human Drugs and TTD | 17 | 10 | 10 | Drugs and targets |
| TAMSULOSIN HYDROCHLORIDE | CHEMBL1200914 | Small molecule | Approval | DailyMed and FDA | 76 | 7 | 6 | Drugs and targets |
| FEXAPOTIDE | CHEMBL3545061 | Protein | Approval | ATC | 4 | 3 | 3 | Drugs and targets |
| TERAZOSIN | CHEMBL611 | Small molecule | Approval | ATC and TTD | 4 | 2 | 2 | Drugs and targets |
| ALFUZOSIN HYDROCHLORIDE | CHEMBL1723 | Small molecule | Approval | DailyMed and TTD | 19 | 1 | 1 | Drugs and targets |
1 to 10 of 64
See all 64 drugsTargets89
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| ADRA1A | Adrenergic receptor alpha-1 | 10 | Adrenergic receptor alpha-1 agonist; Adrenergic receptor alpha-1 antagonist; Alpha-1a adrenergic receptor antagonist | Approval | https://conductscience.org/library/genes/148 | Drugs and targets |
| ADRA1D | Adrenergic receptor alpha-1 | 10 | Adrenergic receptor alpha-1 agonist; Adrenergic receptor alpha-1 antagonist; Alpha-1d adrenergic receptor antagonist | Approval | https://conductscience.org/library/genes/146 | Drugs and targets |
| ADRA1B | Adrenergic receptor alpha-1 | 9 | Adrenergic receptor alpha-1 agonist; Adrenergic receptor alpha-1 antagonist | Approval | https://conductscience.org/library/genes/147 | Drugs and targets |
| PDE5A | cGMP-specific 3',5'-cyclic phosphodiesterase | 4 | Phosphodiesterase 5A inhibitor | Approval | https://conductscience.org/library/genes/8654 | Drugs and targets |
| GNRHR | Gonadotropin-releasing hormone receptor | 3 | Gonadotropin-releasing hormone receptor antagonist | Phase 3 | https://conductscience.org/library/genes/2798 | Drugs and targets |
| SNAP25 | Synaptosomal-associated protein 25 | 3 | Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme; Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor | Phase 3 | https://conductscience.org/library/genes/6616 | Drugs and targets |
| ADRB3 | Beta-3 adrenergic receptor | 2 | Beta-3 adrenergic receptor agonist | Phase 3 | https://conductscience.org/library/genes/155 | Drugs and targets |
| AR | Androgen receptor | 2 | Androgen Receptor antagonist; Androgen Receptor modulator | Phase 2 | https://conductscience.org/library/genes/367 | Drugs and targets |
| CHRM2 | Muscarinic acetylcholine receptor M2 | 2 | Muscarinic acetylcholine receptor M2 antagonist | Phase 3 | https://conductscience.org/library/genes/1129 | Drugs and targets |
| CHRM3 | Muscarinic acetylcholine receptor M3 | 2 | Muscarinic acetylcholine receptor M3 antagonist | Phase 3 | https://conductscience.org/library/genes/1131 | Drugs and targets |
1 to 10 of 89
See all 89 targetsTrials150
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 12 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00090103 | Benign Prostatic Hyperplasia Trial With Dutasteride And Tamsulosin Combination Treatment | Phase 3 | 4,844 | 2010-03-16 | Prostatic Hyperplasia | DUTASTERIDE, TAMSULOSIN | Its record names the disease | ClinicalTrials.gov |
| NCT01299571 | AVODART(Dutasteride) Post-marketing Surveillance(PMS) | 3,977 | 2011-04-18 | Benign Prostatic Hyperplasia, Prostatic Hyperplasia | DUTASTERIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT01018511 | Study of Solifenacin Succinate and Tamsulosin Hydrochloride OCAS in Males With Lower Urinary Tract Symptoms | Phase 3 | 1,334 | 2015-12-17 | Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms | SOLIFENACIN SUCCINATE, TAMSULOSIN HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT03902080 | Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) | Phase 3 | 1,105 | 2024-08-07 | Overactive Bladder | VIBEGRON | Its record names the disease | ClinicalTrials.gov |
| NCT01021332 | Long Term Study of Solifenacin Succinate and Tamsulosin Hydrochloride Oral Controlled Absorption System (OCAS) in Males With Lower Urinary Tract Symptoms | Phase 3 | 1,067 | 2016-01-22 | Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia | SOLIFENACIN SUCCINATE, TAMSULOSIN HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT00384930 | Study of Tadalafil Once-a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia | Phase 2/3 | 1,058 | 2009-08-19 | Benign Prostatic Hyperplasia | TADALAFIL | Its record names the disease | ClinicalTrials.gov |
| NCT01003886 | A Post Marketing Surveillance Study Of Doxazosin Mesylate GITS Among Filipino Patients With Benign Prostatic Hyperplasia (BPH) | 989 | 2011-10-28 | Prostatic Hyperplasia | DOXAZOSIN MESYLATE | Its record names the disease | ClinicalTrials.gov | |
| NCT01937871 | A Study of Tadalafil in Men With Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED) | Phase 3 | 909 | 2017-02-07 | Benign Prostate Hyperplasia, Erectile Dysfunction | TADALAFIL | Its record names the disease | ClinicalTrials.gov |
| NCT01294592 | Comparative Efficacy of Dutasteride Plus Tamulosin With Lifestyle Advice Versus Watchful Waiting Plus Lifestyle Advice in the Management of Treatment naïve Men With Moderately Symptomatic Benign Prostatic Hyperplasia and Prostate Enlargement | Phase 4 | 742 | 2014-06-16 | Prostatic Hyperplasia | DUTASTERIDE, TAMSULOSIN | Its record names the disease | ClinicalTrials.gov |
| NCT01139762 | A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms | Phase 3 | 696 | 2013-02-27 | Benign Prostatic Hyperplasia, Enlarged Prostate | FINASTERIDE, TADALAFIL | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 150
See all 150 trialsComparisons in its trials25
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Vibegron 75 Milligrams (mg) Once Daily (QD) vs Placebo: deaths from any cause | 0 of 553 | 0 of 551 | 1,104 | NCT03902080 | Trial comparisons |
| Vibegron 75 Milligrams (mg) Once Daily (QD) vs Placebo: serious adverse events | 24 of 553 | 16 of 551 | 1,104 | NCT03902080 | Trial comparisons |
| Tadalafil vs Placebo: serious adverse events | 2 of 306 | 1 of 304 | 610 | NCT01460342 | Trial comparisons |
| Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg: deaths from any cause | 1 of 302 | 2 of 305 | 607 | NCT02058368 | Trial comparisons |
| Placebo + Tam 0.2mg vs Dut 0.5 mg + Tam 0.2 mg: serious adverse events | 52 of 302 | 49 of 305 | 607 | NCT02058368 | Trial comparisons |
| Silodosin vs Placebo: serious adverse events | 3 of 233 | 4 of 229 | 462 | NCT00224120 | Trial comparisons |
| Silodosin vs Placebo: serious adverse events | 3 of 233 | 3 of 228 | 461 | NCT00224107 | Trial comparisons |
| Dutasteride vs Placebo: serious adverse events | 20 of 193 | 8 of 184 | 377 | NCT00368979 | Trial comparisons |
| Saw Palmetto vs Placebo: serious adverse events | 18 of 176 | 17 of 181 | 357 | NCT00603304 | Trial comparisons |
| Tadalafil vs Placebo: serious adverse events | 0 of 167 | 0 of 161 | 328 | NCT02431754 | Trial comparisons |
1 to 10 of 25
See all 25 comparisons in its trialsPapers from its trials42
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0010811
GET https://conductscience.org/api/diseases/v1/MONDO_0010811/drugs?page=2